International Clinical Trial: Becotatug Vedotin combined with immune checkpoint inhibitors and gemcitabine as conversion therapy for EGFR-positive locally advanced pancreatic cancer

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129066) titled 'Becotatug Vedotin combined with immune checkpoint inhibitors and gemcitabine as conversion therapy for EGFR-positive locally advanced pancreatic cancer' on July 30.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Huashan Hospital, Fudan University

Condition: locally advanced progressive EGFR-positive pancreatic cancer

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-08-01

Target Sample Size: Experimental group:20;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=333987

Published by HT Digital Conten...